TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05727891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tonabersat
Description: Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Study: NCT04975880

Intervention type: DEVICE
Group type: OTHER
Intervention: SC+ Hemodialysis System
Description: Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
Study: NCT05592678

Intervention type: OTHER
Intervention: Donepezil
Description: Donepezil is administered as a standard of care treatment by the subject's provider.

Intervention type: OTHER
Intervention: Donepezil
Description: Donepezil is administered as a standard of care treatment by the subject's provider.
Study: NCT05461768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion
Study: NCT05130450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.
Study: NCT04636710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
Study: NCT06191263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
Study: NCT04865081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACCIN box
Description: The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
Study: NCT05675696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esophageal Catheter
Description: Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
Study: NCT06195111

Intervention type: DRUG
Intervention: Trifluridine/Tipiracil
Description: This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
Study: NCT06535737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib (Cabometyx) 60, 40 and 20 mg
Study: NCT06569303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years® School Age Basic Parent Training Program
Description: The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: American Academy of Pediatrics, Bright Futures Handouts
Description: Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
Study: NCT06498661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of cervical samples by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Biopsy
Description: Undergo cervical biopsy conducted by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Undergo colposcopy conducted by clinician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocervical Curettage
Description: Undergo endocervical curettage conducted by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision
Description: Undergo cervical excisional procedure conducted by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV Self-Collection
Description: Undertake self-collection of vaginal samples
Study: NCT05252754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsule
Description: Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO, 1-2 hours prior to endoscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rectal Indomethacin
Description: 100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal Indomethacin
Description: 100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
Study: NCT05037097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-165
Description: Dose 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-165
Description: Dose 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-154
Description: Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-154
Description: Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-154
Description: Dose 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021
Description: Dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021
Description: Dose 1
Study: NCT05824208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRENAYOGA - prenatal yoga
Description: The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
Study: NCT04943900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986416
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986416
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT06133816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framed Tobacco Use Message B
Description: Randomly assign patients to receive norming message related to tobacco use (version B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framed Tobacco Use Message B
Description: Randomly assign patients to receive norming message related to tobacco use (version B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framed Tobacco Use Message B
Description: Randomly assign patients to receive norming message related to tobacco use (version B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framed Tobacco Use Message B
Description: Randomly assign patients to receive norming message related to tobacco use (version B).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Randomly assigned patients to be entered into a drawing to receive a $100 gift card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Randomly assigned patients to be entered into a drawing to receive a $100 gift card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Randomly assigned patients to be entered into a drawing to receive a $100 gift card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Randomly assigned patients to be entered into a drawing to receive a $100 gift card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Randomly assigned patients to be entered into a drawing to receive a $100 gift card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
Study: NCT05119296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda)
Description: Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death
Study: NCT05963568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polycap
Description: Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.
Study: NCT05224531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1 Administration
Description: CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1 Administration
Description: CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1 Administration
Description: CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
Study: NCT04767347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 23.0°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 27.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 26.0°C WBGT - Fixed work-to-rest ratio
Description: For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30.5°C WBGT - Fixed work-to-rest ratio
Description: For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30.5°C WBGT - Fixed work-to-rest ratio (high intensity)
Description: For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production
Study: NCT05058430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical salivary stimulator system assigned to subjects with xerostomia
Description: SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Electrical salivary stimulator system assigned to subjects without xerostomia
Description: SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
Study: NCT05032807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard formulation
Description: Cannabidiol 1000mg standard formulation, single dose, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard formulation
Description: Cannabidiol 1000mg standard formulation, single dose, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel formulation
Description: Cannabidiol 1000mg with lipid matrix, single dose, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel formulation
Description: Cannabidiol 1000mg with lipid matrix, single dose, oral
Study: NCT06498661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Test
Description: Undergo HPV testing of self-collected vaginal samples and cervical samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05475340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
Study: NCT05737771

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202213
Description: DWC202213

Intervention type: DRUG
Group type: OTHER
Intervention: DWC202213
Description: DWC202213

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1563
Description: DWJ1563
Study: NCT03979664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activapatch intellidose 2.5 using active Iontophoresis
Description: Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Activapatch intellidose 2.5 using inactive Iontophoresis
Description: Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
Study: NCT05378542

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application usage
Description: The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
Study: NCT05387590

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preventiometer device with wellness coaching
Description: Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
Study: NCT05960955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days
Study: NCT04938635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 60 mg QD
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
Study: NCT05960955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: Oral,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: Oral,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion,Specified dose on specified days
Study: NCT04938635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 60 mg BID
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 120 mg BID
Description: Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
Study: NCT05737771

Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1563
Description: DWJ1563

Intervention type: DRUG
Group type: OTHER
Intervention: DWP16001
Description: DWP16001

Intervention type: DRUG
Group type: OTHER
Intervention: DWP16001
Description: DWP16001
Study: NCT06567119

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SPOT-mRNA01
Description: SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs) ,single-dose subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile isotonic solution, subcutaneous injection